siRNA candidate enters the clinic

Article

SR Pharma has launched a Phase I clinical trial of RTP-801i.

SR Pharma has launched a Phase I clinical trial of RTP-801i, a small interfering RNA (siRNA) therapeutic product licensed from Atugen AG, a subsidiary of SR Pharma.

RTP-801i is based on Atugen's proprietary siRNA technology that modifies the expression of one specific gene target involved in the progression of age-related macular degeneration (AMD).

Pfizer, who licensed the product in September of last year, is funding the trial.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
A photo of the European Medicines Agency (EMA) headquarters. Concept image for Alteogen aflibercept biosimilar approval, Committee for Medicinal Products for Human Use CHMP positive opinion for EYLUXVI. Image credit: ©Ogulcan Aksoy - SCA – stock.adobe.com

Alteogen receives positive CHMP opinion for aflibercept biosimilar EYLUXVI

Martin David Harp
July 28th 2025
Article

According to the company, the EMA’s opinion was based on the “totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package”

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

Two empty medical syringes on a gradient blue and white surface. Concept image for methotrexate for intravitreal injection for retinitis pigmentosa, European Medicines Agency (EMA) orphan drug designation announcement. Image credit: ©cassis – stock.adobe.com

EMA grants orphan designation to ADX-2191 (Aldeyra Therapeutics) for inherited retinal dystrophies

Hattie Hayes
July 24th 2025
Article

Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

The flags of the European Union (left) and Germany (right), in Berlin, in front of the German parliament. Concept image for European Commission, European Medicines Agency and European myopia atropine drug launch. Image credit: ©respiro888 – stock.adobe.com

Germany serves as European launch point for low-dose atropine from Santen (Ryjunea)

Emily Kaiser Maharjan
July 22nd 2025
Article

The SYD-101 atropine formulation is licensed by Santen SA, based in Switzerland, from Sydnexis Inc, based in California

The logo for Eye2Gene, an artificial-intelligence powered ophthalmology diagnostic platform for inherited retinal disease, shows DNA helix imagery and an eye. Image credit: Heidelberg Engineering

AI-powered Eye2Gene uses multimodal imaging to diagnose inherited retinal disease

Abigail Lewis, editorial intern
July 18th 2025
Article

The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests

© 2025 MJH Life Sciences

All rights reserved.